Results 11 to 20 of about 89,537 (296)

Methotrexate Is a JAK/STAT Pathway Inhibitor. [PDF]

PLoS ONE, 2015
The JAK/STAT pathway transduces signals from multiple cytokines and controls haematopoiesis, immunity and inflammation. In addition, pathological activation is seen in multiple malignancies including the myeloproliferative neoplasms (MPNs).
Sally Thomas, Katherine H Fisher, John A Snowden, Sarah J Danson, Stephen Brown, Martin P Zeidler   +5 more
doaj   +3 more sources

Topical JAK inhibitor for refractory skin inflammation in STAT1 GOFTopical JAK inhibitor in STAT1 GOF [PDF]

Journal of Human Immunity
Topical ruxolitinib induced rapid and sustained improvement of refractory skin inflammation in a child with STAT1 GOF disease, highlighting its potential in managing localized inflammation in immune dysregulation.
Valentina Guarnieri, Tiphaine Arlabosse, Claire Booth, Gabriela Petrof   +3 more
doaj   +2 more sources

JAK Inhibitors in Psoriatic Disease

Clinical, Cosmetic and Investigational Dermatology, 2023
Psoriasis is now considered to be the cutaneous phenotype of a systemic inflammatory condition, recognized under the term Psoriatic Disease (PsD). PsD has several extracutaneous manifestations, such as inflammatory articular and entheseal involvement, leading to psoriatic arthritis (PsA), and the less frequent intestinal and ocular manifestations with ...
Megna, Matteo, Potestio, Luca, Ruggiero, Angelo, Cacciapuoti, Sara, Maione, Francesco, Tasso, Marco, Caso, Francesco, Costa, Luisa   +7 more
openaire   +6 more sources

PD-1/PD-L1 inhibitor treatment associated with cardiotoxicity regulated by macrophage polarization and SOCS3/JAK/STAT3 signaling pathway

Central European Journal of Immunology
Cardiotoxicity caused by immune checkpoint inhibitors is one of the most severe and potentially fatal side effects. Hence it is crucial from a therapeutic standpoint to understand the underlying processes and devise countermeasures.
Jiding Fu, Ge Wang, Lisi Zeng, Jie Lin, Yier Wei, Wei Xu, Rui Xu, Lewu Xian   +7 more
doaj   +2 more sources

Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study [PDF]

ACR Open Rheumatology
Objective To evaluate the clinical characteristics and serum cytokine profiles of patients with anti‐MDA5 antibody–positive dermatomyositis with interstitial lung disease (MDA5+ DM‐ILD) treated with JAK inhibitors and to compare survivors and ...
Haruna Matsuo, Tomohiro Koga, Toshimasa Shimizu, Hiroyuki Ide, Serina Koto, Kanako Kojima, Yuya Fujita, Momoko Okamoto, Ayuko Takatani, Takahisa Suzuki, Yuta Matsushita, Atsushi Kawakami   +11 more
doaj   +2 more sources

RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor [PDF]

J Am Chem Soc
We describe the synthesis and biological testing of ruthenium-bipyridine ruxolitinib (RuBiRuxo), a photoreleasable form of ruxolitinib, a JAK inhibitor used as an antitumoral agent in cutaneous T-cell lymphomas (CTCL).
Estefania Rafic (18500620), Bobby B. Shih (18500623), Hannah Miller (3424439), Teresa Palomero (15178926), Roberto Etchenique (159907), Rafael Yuste (53309), Cindy Ma (16407642)   +6 more
core   +2 more sources

Presenting JAK inhibitor safety information to dermatology patients [PDF]

JEADV Clinical Practice
Janus Kinase (JAK) inhibitors are treatment options for dermatologic conditions such as atopic dermatitis, psoriasis, vitiligo, and alopecia areata. Guidance on how to counsel patients on these novel treatments is limited.
Anthony J. Teixeira, Jessica Q. Duong, Shirley P. Parraga, Steven R. Feldman   +3 more
doaj   +2 more sources

Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor [PDF]

, 2021
Background: Type I interferonopathies are a recently established subgroup of autoinflammatory diseases caused by mutations in genes associated with proteasome degradation or cytoplasmic RNA- and DNA-sensing pathways. Objective: This study aimed to unveil
Takahashi, Yoshiyuki, Kitazawa, Hironobu, Ichikawa, Daisuke, Natsume, Jun, Taniguchi, Rieko, Nishino, Ichizo, Kato, Taichi, Fukasawa, Yoshie, Muramatsu, Hideki, Kataoka, Shinsuke, Taketani, Takeshi, Hamada, Motoharu, Miwata, Shunsuke, Nishikawa, Eri, Kojima, Seiji, Okuno, Yusuke, Ohnishi, Hidenori, Suzuki, Kyogo, Yamamoto, Hiroyuki, Murakami, Norihiro, Yamamoto, Hidenori, Nishio, Nobuhiro, Kawashima, Nozomu, Narita, Kotaro, Narita, Atsushi   +24 more
core   +1 more source

JAK inhibitors in autoinflammation [PDF]

Journal of Clinical Investigation, 2018
Interferonopathies are a subset of autoinflammatory disorders with a prominent type I IFN gene signature. Treatment of these patients has been challenging, given the lack of response to common autoinflammatory therapeutics including IL-1 and TNF blockade.
Hal M, Hoffman, Lori, Broderick
openaire   +2 more sources

Tofacitinib

Turkderm Turkish Archives of Dermatology and Venereology, 2022
Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical ...
Nilgün Şentürk
doaj   +1 more source